Osiris Therapeutics
OverviewSuggest Edit
Osiris Therapeutics researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its product Grafix is a cryopreserved placental membrane for treating hard-to-treat acute and chronic wounds, venous leg ulcers, and burns. In addition, the Company offers BIO4, a bone allograft for use in all surgical applications, including spine, trauma, extremity, cranial, and foot and ankle surgery, and Cartiform, a viable chondral allograft that promotes articular cartilage repair to treat focal chondral defects.
| Type | Public | |
| Founded | 1992 | |
| HQ | Columbia, US | Map |
| Website | osiris.com | |
| Employee Ratings | More |
Recent NewsAll News
- Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
- OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
- SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OSIR
Key People/Management at Osiris Therapeutics
Linda Chang
CFO
Jason Keefer
Interim President & CEO, VP of Marketing
Osiris Therapeutics Office Locations
Osiris Therapeutics has an office in Columbia
Columbia, US (HQ)
7015 Albert Einstein Dr
Osiris Therapeutics Financials and Metrics
Osiris Therapeutics Revenue
Osiris Therapeutics's revenue was reported to be $142.82 m in FY, 2018
| USD | |
|---|---|
Revenue (FY, 2018) | 142.8m |
Gross profit (FY, 2018) | 104.7m |
Gross profit margin (FY, 2018), % | 73.3% |
Net income (FY, 2018) | 36.9m |
Market capitalization (16-Apr-2019) | 655.7m |
Closing stock price (16-Apr-2019) | 19.0 |
Cash (31-Dec-2018) | 16.4m |
Osiris Therapeutics's current market capitalization is $655.7 m.
Annual
Annual
Annual
| USD | Y, 2018 |
|---|---|
Revenue/Employee | 420.7k |
Financial Leverage | 1.3 x |
Osiris Therapeutics Online and Social Media Presence
Osiris Therapeutics's Trends
Osiris Therapeutics News and Updates
April 17, 2019
Osiris Therapeutics, Inc. Announces Closing of Acquisition by Smith & Nephew plc
COLUMBIA, Md., April 17, 2019 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ: OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has completed the previously announced sale of Osiris t…
March 27, 2019
OSIRIS SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces an Investigation of Osiris Therapeutics, Inc. (OSIR) Over the Proposed Merger of the Company with Smith & Nephew plc
NEW YORK, March 27, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating the proposed merger of Osiris Therapeutics, Inc. ("OSIRIS" or the "Company") (NASDAQ:OSIR) with Smith & Nephew plc. Click here for more information:...
March 15, 2019
SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.
NEW YORK, March 15, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc. ("OSIR" or the "Company") (NASDAQ: OSIR) in connection with the proposed acquisition of the Company ...
March 13, 2019
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OSIR
NEW YORK, March 13, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Osiris Therapeutics, Inc. ("Osiris" or the "Company") (NasdaqGM:...
March 12, 2019
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.
NEW YORK, March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Smith & Nephew plc. Stockholders will...
March 12, 2019
Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.
LONDON, March 12, 2019 /PRNewswire/ -- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone...
Osiris Therapeutics Blogs
March 12, 2019
Smith & Nephew expands in high growth regenerative medicine market through acquisition of Osiris Therapeutics, Inc.
LONDON , March 12, 2019 /PRNewswire/ -- Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical technology business, announces that it has agreed to acquire Osiris Therapeutics, Inc. (NASDAQ: OSIR), a fast growing company delivering regenerative medicine products, including skin, bone graft a…
November 07, 2018
OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS
The post OSIRIS THERAPEUTICS, INC REPORTS THIRD QUARTER 2018 RESULTS appeared first on Osiris Therapeutics, Inc..
September 11, 2018
Charles A. Rienhart, III
Charles A. Rienhart, III
Kathy.Symes@na…
Tue, 09/11/2018 - 17:12
Charles
A.
Rienhart,
III
Board Member
Charles A. Reinhart, III was appointed to the Board in September 2018. Mr. Reinhart is currently the Chief Financial Officer at Pacira. He joined Pacira …
August 27, 2018
Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial
The post Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial appeared first on…
August 01, 2018
Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018
The post Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 appeared first on Osiris Therapeutics, Inc..
July 11, 2018
Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers
The post Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME™ in the Treatment of Chronic Venous Leg Ulcers appeared first on Osiris Therapeutics, Inc..
Osiris Therapeutics Frequently Asked Questions
When was Osiris Therapeutics founded?
Osiris Therapeutics was founded in 1992.
Who are Osiris Therapeutics key executives?
Osiris Therapeutics's key executives are Linda Chang and Jason Keefer.
How many employees does Osiris Therapeutics have?
Osiris Therapeutics has 342 employees.
What is Osiris Therapeutics revenue?
Latest Osiris Therapeutics annual revenue is $142.8 m.
What is Osiris Therapeutics revenue per employee?
Latest Osiris Therapeutics revenue per employee is $417.6 k.
Who are Osiris Therapeutics competitors?
Competitors of Osiris Therapeutics include GenSight Biologics, Immusoft and Reneuron Group.
Where is Osiris Therapeutics headquarters?
Osiris Therapeutics headquarters is located at 7015 Albert Einstein Dr, Columbia.
Where are Osiris Therapeutics offices?
Osiris Therapeutics has an office in Columbia.
How many offices does Osiris Therapeutics have?
Osiris Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies